{"preliminary_commentary":{"by_channel":{"x_thread":73,"podcast":7,"youtube":4,"x_video":3,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06498479\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"ARTEMIS-008","nct_id":"NCT06498479","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=artemis-008-nct06498479. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive HS-20093 as an intravenous (IV) infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle until a treatment discontinuation criterion is met as specified in the protocol.","label":"HS-20093","type":"EXPERIMENTAL"},{"description":"Participants will receive topotecan until a treatment discontinuation criterion is met as specified in the protocol.","label":"Topotecan","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-08-20","type":"ACTUAL"},"conditions":["Small Cell Lung Cancer"],"enrollment":{"count":461,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"HS-20093","otherNames":[],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-16","lead_sponsor":"Hansoh BioMedical R&D Company","official_title":"ARTEMIS-008：A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"From the date of randomization to the date of death due to any cause; Up to approximately 4.5 years"}],"references":[],"start_date":{"date":"2024-07-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06498479"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/artemis-008-nct06498479"}